Glancy Prongay & Murray LLP Announces Investigation on Behalf of Intersect ENT, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Intersect ENT, Inc. ("Intersect ENT" or the "Company") XENT investors concerning the Company and its officers' possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.

On May 6, 2019, the Company disclosed a first quarter loss of $10.8 million, as well as a lowered guidance for the remainder of 2019. In addition to this news, the Company also reported that its CEO of 11 years will be stepping down on June 5th.

On this news, the Company's share price fell sharply during intraday trading, thereby injuring investors.

If you purchased Intersect ENT securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005704/en/